In a trial of r/r B-ALL patients (ChiCTR-ONC-17013648), serial infusions of CD19 and CD22 CAR-T cells were given to 21 patients who relapsed after HSCT. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.